Neurofibromatosis and Tuberous Sclerosis

Published on 05/03/2015 by admin

Filed under Dermatology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 7820 times

[level-membership-for-dermatology-category]50

Neurofibromatosis and Tuberous Sclerosis

Neurofibromatosis Type 1 (von Recklinghausen Disease)

• Incidence of approximately 1 in 3000 births.

• The NF1 tumor suppressor gene encodes the neurofibromin protein, which negatively regulates the RAS-mitogen-activated protein kinase (MAPK) pathway that promotes cell survival and proliferation.

• Patients with NF1 have a constitutive (germline) NF1 mutation plus a somatic ‘second hit’ mutation inactivating the other copy of the gene in affected tissues (e.g. Schwann cells in neurofibromas, melanocytes in café-au-lait macules [CALMs]).

• The major clinical features of NF1 are outlined in Table 50.1 and depicted in Figs. 50.1–50.5; Fig. 50.6 shows the time course of their development.

• The NIH diagnostic criteria for NF1 (Table 50.2) are met in 97% of patients by age 8 years.

• An approach to infants or young children with ≥6 CALMs is presented in Fig. 50.7.

• Comprehensive NF1 gene analysis with ≥95% sensitivity is available; this can help to establish the diagnosis in atypical presentations or young children not yet meeting criteria.

• DDx: other disorders that can manifest with multiple CALMs are summarized in Table 50.3.

Table 50.3

Other disorders associated with multiple café-au-lait macules (CALMs).

Of note, approximately 30% of the general population has at least one CALM.

image

* Multiple CALMs in small minority of affected individuals.

AD, autosomal dominant; AR, autosomal recessive; JMML, juvenile myelomonocytic leukemia; KP, keratosis pilaris; LEOPARD, lentigines/electrocardiogram abnormalities/ocular hypertelorism/pulmonary stenosis/abnormalities of genitalia/retardation of growth/deafness syndrome; MAPK, mitogen-activated protein kinase; NF1, neurofibromatosis type 1.

• Management of NF1 requires a multidisciplinary approach (Table 50.4).

Tuberous Sclerosis

• Incidence of approximately 1 in 10 000 births.

• Hamartomatous disorder caused by mutations in either the TSC1 or TSC2 gene; both encode proteins (hamartin and tuberin, respectively) that negatively regulate the mammalian target of rapamycin (mTOR) pathway that promotes cell growth.

• TSC2 mutations are associated with more severe disease and are threefold more common than TSC1 mutations in TS patients overall.

• Fig. 50.9 shows the time course for the development of cutaneous findings in TS.

• Hypomelanotic macules may be very subtle or inapparent in individuals with lightly pigmented skin, and a Wood’s light can help to identify them.

• The hypomelanotic macules in TS patients vary in number (few to >100) and size (<1 to >10 cm); their shapes are polygonal more often than resembling an ‘ash leaf’ – rounded at one end, tapered at the other (Fig. 50.10A).

– DDx: nevus depigmentosus is a common (1–5% of healthy children) cause of one or two hypopigmented macule(s) or patch(es); Fig. 50.11 presents an approach to infants/young children with ≥3 hypomelanotic macules.

• Numerous small, confetti-like hypopigmented macules (especially on the extremities) represent a relatively specific finding for TS (Fig. 50.10B).

• Angiofibromas (formerly known as ‘adenoma sebaceum’) are smooth, dome-shaped, pink to red-brown papules (Fig. 50.12); they favor the central face and sometimes coalesce to form plaques.

– DDx: multiple facial angiofibromas can occur in multiple endocrine neoplasia type 1 (MEN1) and Birt–Hogg–Dubé syndrome (see Chapter 91).

• Variants of angiofibromas include cephalic fibrous plaques (e.g. on forehead), ungual fibromas (Koenen tumors; toes > fingers) (Fig. 50.13), and molluscum pendulum (resembling large skin tags) in flexural sites.

• Shagreen patches are connective tissue nevi with a predilection for the lower back; they present as skin-colored, hyperpigmented or (less often) hypopigmented plaques with an uneven, pigskin-like surface (Fig. 50.14).

• Infantile spasms affect ~70% of TS patients, typically beginning at 3–6 months of age; mental deficiency and neuropsychiatric conditions (e.g. autism, attention deficit disorder) are common.

• Additional extracutaneous manifestations and diagnostic criteria are listed in Table 50.5.

• Recommendations for evaluation and management are presented in Table 50.6.

• Rx: systemic administration of mTOR inhibitors (rapamycin [sirolimus], everolimus) for astrocytomas, renal angiomyolipomas, and pulmonary lymphangioleiomyomas; topical rapamycin, lasers (pulsed dye or ablative), and electrosurgery to treat angiofibromas.

For further information see Ch. 61. From Dermatology, Third Edition.

[/level-membership-for-dermatology-category][not-level-membership-for-dermatology-category]50

Neurofibromatosis and Tuberous Sclerosis

Neurofibromatosis Type 1 (von Recklinghausen Disease)

• Incidence of approximately 1 in 3000 births.

• The NF1 tumor suppressor gene encodes the neurofibromin protein, which negatively regulates the RAS-mitogen-activated protein kinase (MAPK) pathway that promotes cell survival and proliferation.

• Patients with NF1 have a constitutive (germline) NF1 mutation plus a somatic ‘second hit’ mutation inactivating the other copy of the gene in affected tissues (e.g. Schwann cells in neurofibromas, melanocytes in café-au-lait macules [CALMs]).

• The major clinical features of NF1 are outlined in Table 50.1 and depicted in Figs. 50.1–50.5; Fig. 50.6 shows the time course of their development.